Amgen Inc. (NASDAQ:AMGN) ranks among the top NASDAQ stocks for retirement. On June 16, Mizuho increased its price target for Amgen Inc. (NASDAQ:AMGN) to $303 from $295 while keeping a Neutral rating on the company's shares, with the firm highlighting MariTide and olpasiran as crucial focal points for the company.

Mizuho said that Novartis and Ionis Pharmaceuticals' pelacarsen Phase 3 Lp(a) research is slated to conclude in the early second half of 2026, which might possibly assist Amgen Inc. (NASDAQ:AMGN).

Mizuho slightly increased its medium-term sales outlook for Amgen Inc. (NASDAQ:AMGN), leading to a minor price target revision. As information from the Novartis and Ionis Phase 3 Lp(a) research becomes available, likely in the first half of 2026, the firm anticipates that market focus will turn toward olpasiran. The olpasiran data is expected to be released at a later time.

Meanwhile, Mizuho noted a potential risk associated with a tax dispute resolution projected no sooner than the latter half of 2026. The firm stated that it is seeking more details on the IRS tax dispute, which, as per Amgen's 10-Q filing, will not be resolved before the latter half of 2026.

Amgen Inc. (NASDAQ:AMGN) is a drug manufacturer that delivers human therapeutics through pharmaceutical wholesale distributors. The company was founded in 1980 and is headquartered in California.

While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.